Dr. Cheryl P Sanchez-Kazi, MD
Claim this profileLoma Linda University Children's Hospital
Studies Focal Segmental Glomerulosclerosis
2 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Cheryl P Sanchez-Kazi, MD is currently running
Liposorber LA-15 Therapy
for Focal Segmental Glomerulosclerosis
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia). Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.
Recruiting1 award N/A5 criteria
LIPOSORBER® LA-15 System
for Focal Segmental Glomerulosclerosis
This trial tests a blood-filtering device called the LIPOSORBER® LA-15 System in adults with kidney issues from FSGS who haven't had success with other treatments or have had severe side effects. The device helps by cleaning the blood to protect the kidneys.
Recruiting1 award N/A2 criteria
More about Cheryl P Sanchez-Kazi, MD
Clinical Trial Related9 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Cheryl P Sanchez-Kazi, MD has experience with
- LIPOSORBER® LA-15 System
- LIPOSORBER® LA-15
Breakdown of trials Cheryl P Sanchez-Kazi, MD has run
Focal Segmental Glomerulosclerosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Cheryl P Sanchez-Kazi, MD specialize in?
Cheryl P Sanchez-Kazi, MD focuses on Focal Segmental Glomerulosclerosis and other conditions. In particular, much of their work with Focal Segmental Glomerulosclerosis has involved treating patients, or patients who are undergoing treatment.
Is Cheryl P Sanchez-Kazi, MD currently recruiting for clinical trials?
Yes, Cheryl P Sanchez-Kazi, MD is currently recruiting for 2 clinical trials in Loma Linda California. If you're interested in participating, you should apply.
Are there any treatments that Cheryl P Sanchez-Kazi, MD has studied deeply?
Yes, Cheryl P Sanchez-Kazi, MD has studied treatments such as LIPOSORBER® LA-15 System, LIPOSORBER® LA-15.
What is the best way to schedule an appointment with Cheryl P Sanchez-Kazi, MD?
Apply for one of the trials that Cheryl P Sanchez-Kazi, MD is conducting.
What is the office address of Cheryl P Sanchez-Kazi, MD?
The office of Cheryl P Sanchez-Kazi, MD is located at: Loma Linda University Children's Hospital, Loma Linda, California 92354 United States. This is the address for their practice at the Loma Linda University Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.